Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Voyager Therapeutics stock

Learn how to easily invest in Voyager Therapeutics stock.

Voyager Therapeutics Inc is a biotechnology business based in the US. Voyager Therapeutics shares (VYGR) are listed on the NASDAQ and all prices are listed in US Dollars. Voyager Therapeutics employs 177 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Voyager Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VYGR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Voyager Therapeutics stock price (NASDAQ: VYGR)

Use our graph to track the performance of VYGR stocks over time.

Voyager Therapeutics shares at a glance

Information last updated 2022-01-11.
Latest market close$2.94
52-week range$2.46 - $9.15
50-day moving average $3.12
200-day moving average $3.72
Wall St. target price$6.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.47

Buy Voyager Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
$125 - $625
Open and fund an account with $25,000 - $250,000+

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Voyager Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Voyager Therapeutics price performance over time

Historical closes compared with the close of $2.94 from 2022-01-14

1 week (2022-01-12) 2.08%
1 month (2021-12-17) -1.67%
3 months (2021-10-15) N/A
6 months (2021-07-19) -12.24%
1 year (2021-01-19) -66.09%
2 years (2020-01-17) -78.68%
3 years (2019-01-18) 8.26
5 years (2017-01-18) 11.58

Is Voyager Therapeutics stock undervalued or overvalued?

Valuing Voyager Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Voyager Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Voyager Therapeutics's EBITDA

Voyager Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.1 million.

The EBITDA is a measure of a Voyager Therapeutics's overall financial performance and is widely used to measure a its profitability.

Voyager Therapeutics financials

Revenue TTM $15.9 million
Gross profit TTM $62.4 million
Return on assets TTM -27.79%
Return on equity TTM -73.2%
Profit margin 0%
Book value $2.31
Market capitalisation $107.8 million

TTM: trailing 12 months

Voyager Therapeutics share dividends

We're not expecting Voyager Therapeutics to pay a dividend over the next 12 months.

Voyager Therapeutics share price volatility

Over the last 12 months, Voyager Therapeutics's shares have ranged in value from as little as $2.46 up to $9.15. A popular way to gauge a stock's volatility is its "beta".

VYGR.US volatility(beta: 1.19)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Voyager Therapeutics's is 1.1901. This would suggest that Voyager Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Voyager Therapeutics overview

Voyager Therapeutics, Inc. , a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc. , as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc.

Frequently asked questions

What percentage of Voyager Therapeutics is owned by insiders or institutions?
Currently 13.98% of Voyager Therapeutics shares are held by insiders and 65.098% by institutions.
How many people work for Voyager Therapeutics?
Latest data suggests 177 work at Voyager Therapeutics.
When does the fiscal year end for Voyager Therapeutics?
Voyager Therapeutics's fiscal year ends in December.
Where is Voyager Therapeutics based?
Voyager Therapeutics's address is: 75 Sidney Street, Cambridge, MA, United States, 02139
What is Voyager Therapeutics's ISIN number?
Voyager Therapeutics's international securities identification number is: US92915B1061
What is Voyager Therapeutics's CUSIP number?
Voyager Therapeutics's Committee on Uniform Securities Identification Procedures number is: 92915B102

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site